BioCentury
ARTICLE | Finance

Why Tesaro went NOVA

Why 'best case scenario' boosts Tesaro on PARP data

July 11, 2016 7:00 AM UTC

Even though one marketed PARP inhibitor already has demonstrated that its mechanism works as maintenance therapy in platinum-sensitive ovarian cancer, Tesaro Inc. (NASDAQ:TSRO) soared on its positive Phase III data for niraparib (MK-4827) because it was "a best case scenario," according to one investor.

On June 29, Tesaro climbed $40.19 (108%) to $77.40 after it announced niraparib met the primary endpoint of improving progression-free survival (PFS) in the 500-patient Phase III NOVA trial. The study evaluated the oral PARP inhibitor as maintenance therapy in platinum-sensitive ovarian cancer patients with and without germline BRCA mutations. ...